Cargando…
OATD-02 Validates the Benefits of Pharmacological Inhibition of Arginase 1 and 2 in Cancer
SIMPLE SUMMARY: Arginase 1 and 2 are drivers of multiple immunosuppressive mechanisms and tumour-specific metabolic adaptations. Pharmacological inhibition of extracellular ARG1 has shown antitumour efficacy in various syngeneic tumour models, however, the importance of ARG2 as a therapeutic target...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406419/ https://www.ncbi.nlm.nih.gov/pubmed/36010962 http://dx.doi.org/10.3390/cancers14163967 |
_version_ | 1784774116291641344 |
---|---|
author | Grzybowski, Marcin Mikołaj Stańczak, Paulina Seweryna Pomper, Paulina Błaszczyk, Roman Borek, Bartłomiej Gzik, Anna Nowicka, Julita Jędrzejczak, Karol Brzezińska, Joanna Rejczak, Tomasz Güner-Chalimoniuk, Nazan Cemre Kikulska, Agnieszka Mlącki, Michał Pęczkowicz-Szyszka, Jolanta Olczak, Jacek Gołębiowski, Adam Dzwonek, Karolina Dobrzański, Paweł Zasłona, Zbigniew |
author_facet | Grzybowski, Marcin Mikołaj Stańczak, Paulina Seweryna Pomper, Paulina Błaszczyk, Roman Borek, Bartłomiej Gzik, Anna Nowicka, Julita Jędrzejczak, Karol Brzezińska, Joanna Rejczak, Tomasz Güner-Chalimoniuk, Nazan Cemre Kikulska, Agnieszka Mlącki, Michał Pęczkowicz-Szyszka, Jolanta Olczak, Jacek Gołębiowski, Adam Dzwonek, Karolina Dobrzański, Paweł Zasłona, Zbigniew |
author_sort | Grzybowski, Marcin Mikołaj |
collection | PubMed |
description | SIMPLE SUMMARY: Arginase 1 and 2 are drivers of multiple immunosuppressive mechanisms and tumour-specific metabolic adaptations. Pharmacological inhibition of extracellular ARG1 has shown antitumour efficacy in various syngeneic tumour models, however, the importance of ARG2 as a therapeutic target has only been demonstrated by genetic deletion studies. This is the first study validating the benefits of pharmacological inhibition of ARG2 in cancer. Our work describes OATD-02 as a potent dual ARG1/ARG2 inhibitor with a cellular activity (necessary for targeting ARG2) exhibiting immunomodulatory and direct antitumour efficacy in animal models. Our results present OATD-02 as an attractive option for combination with other immunotherapeutics, such as PD-1/PD-L1 antibodies or IDO1 inhibitors, especially in the therapy of particularly resistant hypoxic tumours. The presented findings provided the rationale for planning first-in-human clinical trials for OATD-02 in cancer patients. ABSTRACT: Background: Arginases play essential roles in metabolic pathways, determining the fitness of both immune and tumour cells. Along with the previously validated role of ARG1 in cancer, the particular significance of ARG2 as a therapeutic target has emerged as its levels correlate with malignant phenotype and poor prognosis. These observations unveil arginases, and specifically ARG2, as well-validated and promising therapeutic targets. OATD-02, a new boronic acid derivative, is the only dual inhibitor, which can address the benefits of pharmacological inhibition of arginase 1 and 2 in cancer. Methods: The inhibitory activity of OATD-02 was determined using recombinant ARG1 and ARG2, as well as in a cellular system using primary hepatocytes and macrophages. In vivo antitumor activity was determined in syngeneic models of colorectal and kidney carcinomas (CT26 and Renca, respectively), as well as in an ARG2-dependent xenograft model of leukaemia (K562). Results: OATD-02 was shown to be a potent dual (ARG1/ARG2) arginase inhibitor with a cellular activity necessary for targeting ARG2. Compared to a reference inhibitor with predominant extracellular activity towards ARG1, we have shown improved and statistically significant antitumor efficacy in the CT26 model and an immunomodulatory effect reflected by Treg inhibition in the Renca model. Importantly, OATD-02 had a superior activity when combined with other immunotherapeutics. Finally, OATD-02 effectively inhibited the proliferation of human K562 leukemic cells both in vitro and in vivo. Conclusions: OATD-02 is a potent small-molecule arginase inhibitor with optimal drug-like properties, including PK/PD profile. Excellent activity against intracellular ARG2 significantly distinguishes OATD-02 from other arginase inhibitors. OATD-02 represents a very promising drug candidate for the combined treatment of tumours, and is the only pharmacological tool that can effectively address the benefits of ARG1/ARG2 inhibition. OATD-02 will enter clinical trials in cancer patients in 2022. |
format | Online Article Text |
id | pubmed-9406419 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94064192022-08-26 OATD-02 Validates the Benefits of Pharmacological Inhibition of Arginase 1 and 2 in Cancer Grzybowski, Marcin Mikołaj Stańczak, Paulina Seweryna Pomper, Paulina Błaszczyk, Roman Borek, Bartłomiej Gzik, Anna Nowicka, Julita Jędrzejczak, Karol Brzezińska, Joanna Rejczak, Tomasz Güner-Chalimoniuk, Nazan Cemre Kikulska, Agnieszka Mlącki, Michał Pęczkowicz-Szyszka, Jolanta Olczak, Jacek Gołębiowski, Adam Dzwonek, Karolina Dobrzański, Paweł Zasłona, Zbigniew Cancers (Basel) Article SIMPLE SUMMARY: Arginase 1 and 2 are drivers of multiple immunosuppressive mechanisms and tumour-specific metabolic adaptations. Pharmacological inhibition of extracellular ARG1 has shown antitumour efficacy in various syngeneic tumour models, however, the importance of ARG2 as a therapeutic target has only been demonstrated by genetic deletion studies. This is the first study validating the benefits of pharmacological inhibition of ARG2 in cancer. Our work describes OATD-02 as a potent dual ARG1/ARG2 inhibitor with a cellular activity (necessary for targeting ARG2) exhibiting immunomodulatory and direct antitumour efficacy in animal models. Our results present OATD-02 as an attractive option for combination with other immunotherapeutics, such as PD-1/PD-L1 antibodies or IDO1 inhibitors, especially in the therapy of particularly resistant hypoxic tumours. The presented findings provided the rationale for planning first-in-human clinical trials for OATD-02 in cancer patients. ABSTRACT: Background: Arginases play essential roles in metabolic pathways, determining the fitness of both immune and tumour cells. Along with the previously validated role of ARG1 in cancer, the particular significance of ARG2 as a therapeutic target has emerged as its levels correlate with malignant phenotype and poor prognosis. These observations unveil arginases, and specifically ARG2, as well-validated and promising therapeutic targets. OATD-02, a new boronic acid derivative, is the only dual inhibitor, which can address the benefits of pharmacological inhibition of arginase 1 and 2 in cancer. Methods: The inhibitory activity of OATD-02 was determined using recombinant ARG1 and ARG2, as well as in a cellular system using primary hepatocytes and macrophages. In vivo antitumor activity was determined in syngeneic models of colorectal and kidney carcinomas (CT26 and Renca, respectively), as well as in an ARG2-dependent xenograft model of leukaemia (K562). Results: OATD-02 was shown to be a potent dual (ARG1/ARG2) arginase inhibitor with a cellular activity necessary for targeting ARG2. Compared to a reference inhibitor with predominant extracellular activity towards ARG1, we have shown improved and statistically significant antitumor efficacy in the CT26 model and an immunomodulatory effect reflected by Treg inhibition in the Renca model. Importantly, OATD-02 had a superior activity when combined with other immunotherapeutics. Finally, OATD-02 effectively inhibited the proliferation of human K562 leukemic cells both in vitro and in vivo. Conclusions: OATD-02 is a potent small-molecule arginase inhibitor with optimal drug-like properties, including PK/PD profile. Excellent activity against intracellular ARG2 significantly distinguishes OATD-02 from other arginase inhibitors. OATD-02 represents a very promising drug candidate for the combined treatment of tumours, and is the only pharmacological tool that can effectively address the benefits of ARG1/ARG2 inhibition. OATD-02 will enter clinical trials in cancer patients in 2022. MDPI 2022-08-17 /pmc/articles/PMC9406419/ /pubmed/36010962 http://dx.doi.org/10.3390/cancers14163967 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Grzybowski, Marcin Mikołaj Stańczak, Paulina Seweryna Pomper, Paulina Błaszczyk, Roman Borek, Bartłomiej Gzik, Anna Nowicka, Julita Jędrzejczak, Karol Brzezińska, Joanna Rejczak, Tomasz Güner-Chalimoniuk, Nazan Cemre Kikulska, Agnieszka Mlącki, Michał Pęczkowicz-Szyszka, Jolanta Olczak, Jacek Gołębiowski, Adam Dzwonek, Karolina Dobrzański, Paweł Zasłona, Zbigniew OATD-02 Validates the Benefits of Pharmacological Inhibition of Arginase 1 and 2 in Cancer |
title | OATD-02 Validates the Benefits of Pharmacological Inhibition of Arginase 1 and 2 in Cancer |
title_full | OATD-02 Validates the Benefits of Pharmacological Inhibition of Arginase 1 and 2 in Cancer |
title_fullStr | OATD-02 Validates the Benefits of Pharmacological Inhibition of Arginase 1 and 2 in Cancer |
title_full_unstemmed | OATD-02 Validates the Benefits of Pharmacological Inhibition of Arginase 1 and 2 in Cancer |
title_short | OATD-02 Validates the Benefits of Pharmacological Inhibition of Arginase 1 and 2 in Cancer |
title_sort | oatd-02 validates the benefits of pharmacological inhibition of arginase 1 and 2 in cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406419/ https://www.ncbi.nlm.nih.gov/pubmed/36010962 http://dx.doi.org/10.3390/cancers14163967 |
work_keys_str_mv | AT grzybowskimarcinmikołaj oatd02validatesthebenefitsofpharmacologicalinhibitionofarginase1and2incancer AT stanczakpaulinaseweryna oatd02validatesthebenefitsofpharmacologicalinhibitionofarginase1and2incancer AT pomperpaulina oatd02validatesthebenefitsofpharmacologicalinhibitionofarginase1and2incancer AT błaszczykroman oatd02validatesthebenefitsofpharmacologicalinhibitionofarginase1and2incancer AT borekbartłomiej oatd02validatesthebenefitsofpharmacologicalinhibitionofarginase1and2incancer AT gzikanna oatd02validatesthebenefitsofpharmacologicalinhibitionofarginase1and2incancer AT nowickajulita oatd02validatesthebenefitsofpharmacologicalinhibitionofarginase1and2incancer AT jedrzejczakkarol oatd02validatesthebenefitsofpharmacologicalinhibitionofarginase1and2incancer AT brzezinskajoanna oatd02validatesthebenefitsofpharmacologicalinhibitionofarginase1and2incancer AT rejczaktomasz oatd02validatesthebenefitsofpharmacologicalinhibitionofarginase1and2incancer AT gunerchalimoniuknazancemre oatd02validatesthebenefitsofpharmacologicalinhibitionofarginase1and2incancer AT kikulskaagnieszka oatd02validatesthebenefitsofpharmacologicalinhibitionofarginase1and2incancer AT mlackimichał oatd02validatesthebenefitsofpharmacologicalinhibitionofarginase1and2incancer AT peczkowiczszyszkajolanta oatd02validatesthebenefitsofpharmacologicalinhibitionofarginase1and2incancer AT olczakjacek oatd02validatesthebenefitsofpharmacologicalinhibitionofarginase1and2incancer AT gołebiowskiadam oatd02validatesthebenefitsofpharmacologicalinhibitionofarginase1and2incancer AT dzwonekkarolina oatd02validatesthebenefitsofpharmacologicalinhibitionofarginase1and2incancer AT dobrzanskipaweł oatd02validatesthebenefitsofpharmacologicalinhibitionofarginase1and2incancer AT zasłonazbigniew oatd02validatesthebenefitsofpharmacologicalinhibitionofarginase1and2incancer |